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Abstract
We investigated the roles played by the cysteine proteases cathepsin B and cathepsin L (brucipain) in the pathogenesis of
Trypansoma brucei brucei in both an in vivo mouse model and an in vitro model of the blood–brain barrier. Doxycycline
induction of RNAi targeting cathepsin B led to parasite clearance from the bloodstream and prevent a lethal infection in the
mice. In contrast, all mice infected with T. brucei containing the uninduced Trypanosoma brucei cathepsin B (TbCatB) RNA
construct died by day 13. Induction of RNAi against brucipain did not cure mice from infection; however, 50% of these mice
survived 60 days longer than uninduced controls. The ability of T. b. brucei to cross an in vitro model of the human blood–brain
barrier was also reduced by brucipain RNAi induction. Taken together, the data suggest that while TbCatB is the more likely
target for the development of new chemotherapy, a possible role for brucipain is in facilitating parasite entry into the brain.
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Introduction
Subspecies of Trypanosoma brucei are the causative agents of
human African trypanosomiasis. In vitro studies utilizing both
small molecule cysteine protease inhibitors and RNA interference
(RNAi) have implicated the Clan CA (papain) family of cysteine
proteases as critical to the successful lifecycle of Trypanosoma brucei
brucei (T. b. brucei) [1,2]. In vivo studies have demonstrated that
cysteine protease inhibitors prolong the lives of mice infected with
lethal inocula of trypanosomes [1,3]. There are two distinct Clan
CA cysteine proteases identified in the T. brucei genome. Brucipain
(aka trypanopain-Tb, rhodesain) is a cathepsin L-like protease
responsible for the bulk of protease activity in the organism [2].
Trypanosoma brucei cathepsin B (TbCatB) is a more recently
characterized protease that is upregulated in the bloodstream
stage of the parasite [2]. In in vitro studies, RNAi of TbCatB
produced swelling of the endosome compartment analogous to
that seen with class-specific cysteine protease inhibitors [1,2] and
led to arrest of trypanosome replication and death. In contrast,
knockdown of brucipain by RNAi in vitro produced no detectable
phenotypic changes. However, it was hypothesized that this
enzyme might play a role in the degradation of mistargeted
glycosylphosphatidylinisotol (GPI) anchored proteins, VSG turn-
over, disruption of the blood–brain barrier, or degradation of host
immunoglobulin [4,5] While RNAi with cultured parasites can
provide important insights into the role of a specific gene product
in parasite replication and viability, a role in pathogenesis, as
proposed for brucipain, can only be validated in vivo. We show
that introduction of RNAi from a tetracycline-inducible promoter
can be achieved in vivo in a mouse model of T. b. brucei infection,
and show that transcriptional silencing of either of these two
proteases alters the course of T. b. brucei infection [6].
Materials and Methods
Bloodstream T. brucei strain 90-13
Bloodstream T. brucei strain 90-13 was electroporated with
plasmids containing either brucipain (TbRho), TbCatB, or GFP
transgenes [2]. The plasmid used, pZJM, allows transfected
organisms to be induced to produce RNAi in the presence of
tetracycline. The brucipain RNAi construct used for this study is
one of three partial open reading frames (ORF) of brucipain used
to down regulate its message in vitro. R1 encodes a cDNA that
corresponding to the first 597 nucleotides of brucipain ORF. R2
encodes a cDNA encoding the middle 400 nucleotides of the
brucipain ORF and R3 encodes a partial cDNA encoding the last
300 nucleotides of the brucipain ORF. Each of these constructs
were capable of efficiently and specifically silencing the mRNA of
brucipain in vitro. The same T. b. brucei clones expressing the R1
construct used in a previous study [2]. The TbCatB transgene has
been described in detail previously [2]. To generate the GFP
transgene, the gene encoding GFP (714 nucleotides) was amplified
from the pHD-HX-GFP vector [7]. Methods for electroporation
and selection of stable transformants have been described [2].
Trypanosome culture and infection of mice
Bloodstream form (BSF) 90-13 cells expressing T7 RNA
polymerase and tetracycline repressor protein were maintained
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in HMI-9 medium [8]. Five BALB/c mice per group (6–8 weeks
old) were infected by intraperitoneal injection with 600 parasites
carrying pZJMTbRho, pZJMTbCatB, or pZJMGFP plasmids or
with control 90-13 parasites. To rule out any direct effects of
doxycycline on the course of trypanosome infection, two
additional groups of mice were infected with the parental T. b.
brucei strain 90-13. One group was given doxycycline-containing
food (200-mg/Kg, Bioserv Corporation, San Diego, CA) and
water containing 1 mg/ml doxycycline hyclate (Sigma-Aldrich),
the second group was given standard food and water.
Six other groups of mice were infected with T. b. brucei
containing an RNAi-producing plasmid for brucipain
(pZJMTbRho), cathepsin B (pZJMTbCatB), or GFP (pZJMGFP).
Three control (uninduced) groups were given standard food and
water, and another three groups were given doxycycline
containing food and water. The two groups infected with
pZJMGFP served as a control for a gene that is not found in
the trypanosome. Mice were monitored every other day for weight
loss, general appearance, and behavior. Experiments were carried
out in accordance with protocols approved by the Institutional
Animal Care and Use Committee (IACUC) at UCSF.
The in vitro model of the human blood–brain barrier
(BBB)
We used a human brain microvascular endothelial cell (BMEC)
line whose phenotypic expression was stabilized by immortalization
with pSVT, a pBR322-based plasmid containing the DNA sequence
encoding the simian virus 40 large-T antigen [9]. Similar to the
primary human BMEC cell line (XIII) from which they were
derived, the transfected human BMECs are positive for FVIII-Rag,
carbonic anhydrase IV, and Ulex europeus agglutinin I; take up
acetylated low-density lipoprotein; and express gamma glutamyl
transpeptidase [9,10]. Human BMECs were cultured at 37uC in
medium 199 (GIBCO) supplemented with 20% heat-inactivated
fetal bovine serum and 16 Glutamax (GIBCO) in a humidified
environment of 95% air, 5% CO2. The cells were grown to
confluence on 6.5-mm-diameter collagen-coated Costar Transwell
inserts with a pore size of 3.0 m until transendothelial electrical
resistance (TEER) measurements exceeded 25 cm2 [11]. For the
transmigration study, the parasites were added to the top of the
human BMEC-containing inserts. The cultures were incubated with
and without tetracycline (100 ng/ml) in triplicate at 37uC, and the
number of parasites present at the bottom chamber were determined
by counting aliquots in the Neubauer chamber.
Real-time reverse transcription RT-PCR
Gene transcripts for brucipain were quantified in freshly isolated
T. b. brucei from mice infected with pZJMTbRho at five days post
infection. Blood was separated in a DEAE-sepharose column as
previously described [12]. Total RNA extraction from T. b. brucei
was performed using the TRIzol reagent (Invitrogen, Carlsbad,
CA). RT-PCR, the one-step RT-PCR kit (Invitrogen, Carlsbad,
CA), and gene-specific primers forward 59-ATACGCAACG-
TTTGGTGTGA-39 and reverse 59CCTTCGATGTTGCCGA-
TAGT -39 were used to amplify brucipain. The relative amount of
gene transcripts was calculated using methods previously described
[13].
Preparation of trypanosome lysates
Parasites were purified from mice infected with parental 90-13
or pZJMTbRho. As reported previously [12], T. b. brucei from
infected mice were harvested by centrifugation, washed once in
PBS-containing 1% glucose, and resuspended in lysis buffer (1.0%
Triton X-100, 10 mM Tris pH 7.5, 25 mM KCl, 150 mM NaCl,
1 mM MgCl2, 0.2 mM EDTA, 1 mM dithiothreitol, 20%
glycerol). The lysates were incubated on ice for 20 min and
cleared by centrifugation at 16,000 g for 15 min at +4uC. Protein
concentration of was determined by the Bradford assay (Bio-Rad).
Western blots of trypanosome lysates following RNAi
induction
Ten mg of trypanosome lysate was resolved by 15% SDS-PAGE
and transferred a to polyvinylidene difluoride (PVDF) membrane.
After transferring and blocking, the PVDF membranes were
incubated with rabbit anti-brucipain antiserum (1:2500 dilution) or
anti-TbcatB 1:2000 [14] for 1 h and washed three times for five min
with TBST (10 mMTris, pH 7.4, 150 mMNaCl, 0.4% Tween 20).
After the third wash, horseradish peroxidase-conjugated donkey
anti-rabbit IgG (1:1,000 dilution) was added to the blots for 1 h. The
blots were washed again in the same buffer three times for five min
and examined by ECL (Amersham Biosciences).
Radiolabeling of cysteine protease active sites with 125I-
labeled inhibitors
Equal amounts of trypanosome lysate (10 mg) were labeled with
125I-DCG-04 [15] in the presence of 2 mM dithiothreitol for
45 min at room temperature and subjected to SDS-PAGE.
Quantification of labeled enzymes was determined by Phosphoi-
mager analysis (Molecular Dynamics).
Statistical analysis
Data were analyzed using the Mann-Whitney nonparametric
test to determine the statistical difference in spleen weight in
induced versus un-induced infected mice. Chi-square analysis was
performed to determine the significant difference in survival.
Results/Discussion
The goal of these experiments was to validate the in vitro effects
of RNAi on TbcatB in an in vivo disease model of African
trypanosomiasis, and to explore a potential role of brucipain as a
virulence factor. For safety reasons we conducted the knockdown
experiment in the human non-infective strain T. b. brucei which
has been traditionally grown and studied in mice. Doxycycline by
itself produced no significant alteration (+/21 day) in the course of
T. b. brucei 90-13 infections (Fig. 1A). Equivalent levels of
parasitemia and splenomegaly were observed in mice whether or
not they were maintained on a doxycycline-containing diet (not
Author Summary
African trypanosomiasis, or sleeping sickness, is caused by
the single-cell parasite Trypanosoma brucei (T. brucei). Two
parasite-derived enzyme proteins have been hypothesized
to play an important role in the viability of the parasite or
its ability to produce disease in the human host. Utilizing
RNA interference that blocks the production of these
proteins in the parasite, we show that elimination of
parasite cathepsin B cures infection in mice. RNAi of the
second enzyme protein, brucipain, results in the prolon-
gation of life of half the infected mice, but does not cure.
Further experiments carried out in a culture system show
that brucipain facilitates the migration of parasites across a
model of the blood–brain barrier. This suggests that while
brucipain is not necessary for the viability of the
organisms, it may play a role in infection by allowing
parasites to reach the central nervous system and produce
the severe second stage of sleeping sickness.
Trypanosoma brucei Cysteine Proteases
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Figure 1. Survival analysis for mice infected with
T. b. brucei. (A) Kaplan-Meier survival analysis for mice
infected with T. b. brucei not transfected with the RNAi
construct but given an inducing dose of doxycycline
(red) versus standard food and water (blue) (n = 5 in each
group). (B) Infection with trypanosomes containing the
RNAi plasmid for brucipain plus or minus induction by
doxycycline. Brucipain RNAi resulted in prolonged
survival of three out of the five mice (p = 0.004)
(experiment was conducted twice with the same result).
(C) Infection with parasite containing RNAi plasmid for
TbCatB plus or minus induction by doxycycline. Note
that all five mice infected with parasites in which
cathepsin B RNAi was induced survived until the
experiment was terminated. (D) Spleen weights in mice
infected with cathepsin B RNAi parasites and induced
with doxycyline were within normal range compared to
uninfected controls.
doi:10.1371/journal.pntd.0000298.g001
Trypanosoma brucei Cysteine Proteases
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shown). The in vivo induction of RNAi against brucipain in T. b.
brucei did not cure infection, but extended the survival of three out
of five mice beyond 60 days (Fig. 1B) the experiment was repeated
twice with the same result. All mice infected with trypanosomes
having the brucipain transcript knockdown had parasitemia and
splenomegaly equivalent to that seen in control mice at the time of
their sacrifice (not shown). Splenomegaly (quantified by spleen
weight) is a convenient gross pathological marker of disease
burden [16]. Analysis of mRNA levels in trypanosomes isolated
from infected mice confirmed 60% reduction in the level of
brucipain mRNA (Fig. 2A). The level of cathepsin B mRNA was
not affected by RNAi induction against brucipain in pZJMTbRho
induced parasites (Fig. 2B). Active site labeling of brucipain in
trypanosomes purified from mouse blood confirmed 60%
reduction in brucipain protease activity (Fig. 3C). Endogenous
activity levels of brucipain and cathepsin B, quantified by DCG-04
labeling of purified parasites from mice infected with 90-13 strain,
confirmed that brucipain was more abundant than cathepsin B
(Fig. 3D), consistent with previously published data [2,14]. A
control cell line with an insert of GFP was generated to investigate
the role of RNAi plasmid construct itself on the parasites in vivo.
Figure 2. RNAi reduces expression of brucipain mRNA in
parasites isolated from mice. (A) Evidence that RNAi reduces
expression of brucipain mRNA in parasites isolated from mice. Mice
infected with the brucipain RNAi-containing plasmids were either
induced with doxycycline or left un-induced. (B) RNAi induced against
brucipain did not decrease mRNA level for cathepsin B.
doi:10.1371/journal.pntd.0000298.g002
Figure 3. RNAi reduces brucipain protein and protease activity.
(A) Equal amounts of protein were resolved by 15% SDS-PAGE, stained
with anti-rhodesain antibody, and visualized by Western blot. Brucipain
protein level is decreased after RNAi induction in pZJMTbRho parasites
recovered from infected mice but the level of cathepsin B is not
decreased after brucipain RNAi induction in pZJMTbRho parasites. (B)
Brucipain activity is also decreased by 60% with brucipain RNAi
induction. The level of brucipain activity in pZJMRho transfected
parasites purified from mice was determined with the active site tag
125I-DCG-04, visualized by autoradiography, and quantified by Phos-
phorImager analysis. (C) In the absence of RNAi bands of brucipain and
TbCatB activity can be identified in purified parasites from mice infected
with 90-13 labeled with the active site tag 125I-DCG-04 and visualized by
autoradiography.
doi:10.1371/journal.pntd.0000298.g003
Trypanosoma brucei Cysteine Proteases
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No difference was seen in mouse pathology or in brucipain or
cathepsin B levels with GFP-induced parasites (data not shown).
In vivo induction of TbCatB RNAi resulted in survival of all five
mice for up to two months post infection, after which time the
experiment was terminated (Fig. 1C). Un-induced mice began to
die 13 days after infection. No trypanosomes were detected in the
blood of mice infected with pZJMTbCatB trypanosomes after
induction of RNAi with doxycycline. These mice also had normal
spleen weights compared to un-induced controls (Fig. 1D). Control
mice with no doxycycline died between day 11 and 15 post
infection. The last day on which untreated mice died from the
trypanosome infection may vary depending on the exact parasite
inoculum received and other host defense and host metabolic
factors (Fig. 1A vs 1B).
The demonstration that doxycycline induction of RNAi can be
achieved in parasites within an animal model of infection is an
important technological advance that should encourage the use of
this approach by other investigators. The failure of parasites to
establish infection with TbCatB RNAi might have been predicted
from in vitro assays. However demonstration in an in vivo model of
infection is a significant and necessary validation of the key role of
TbCatB in infection. The effect of reducing transcripts for the
cathepsin L-like trypanosome protease (brucipain) on the progres-
sion of the infection was not predicted from in vitro assays. The
effect of brucipain RNAi suggests that the cathepsin L protease
might play a role as a virulence factor in in vivo infections, where
host tissue tropism and the host immune response add new layers
of complexity.
In conclusion, gene-specific RNAi can be induced in blood-
stream parasites in an experimental model of trypanosome
infection. Induction of RNAi targeting TbCatB transcripts in vivo
correlates with the results observed in previous in vitro RNAi
experiments [1,2]. In the mouse model of infection, RNAi of
TbCatB rescued mice from a lethal T. b. brucei infection, resulting
in no splenomegaly and no detectable parasites in blood. While
induction of RNAi against brucipain in two independent
experiments did not cure mice of their infection, it did significantly
prolong the survival of five out of ten mice. Since RNAi led to a
60% reduction of brucipain activity (Fig. 3C), it is still possible that
a 100% knockdown might uncover a more direct role for
brucipain in parasite viability; brucipain knockouts are being
pursued as strategy to more clearly delineate the role of brucipain.
However, even the modest RNAi knockdown achieved for
TbCatB (quantified in [2]) had a profound negative effect on
parasite viability both in vitro [5] and in vivo, suggesting that T.
brucei cathepsin B is the more likely target for protease inhibitors as
chemotherapy against human African trypanosomiasis [17].
While the residual brucipain activity seen after RNAi induction
might be responsible for disease progression in two of the mice
shown in (Fig. 1B), an alternative conclusion is that brucipain plays
a specific role in Trypanosoma pathogenesis in vivo, but not in
parasite viability per se. Nikolskaia et al. [5] showed that a cysteine
protease inhibitor, known to target brucipain, blocked the ability
of African trypanosomes to cross a model of the blood–brain
barrier (BBB) [5]. Using this in vitro model of the blood–brain
barrier, we confirmed that brucipain is required for African
trypanosomes to effectively cross the brain endothelial barriers.
Without tetracycline 3.54E+0461.41E+03 (mean6SEM) of the
initial brucipain RNAi trypanosome (pZJMTbRho–tet) inoculum
crossed the endothelial cell barrier (1–2%) (Fig. 4). This is
comparable to those noted for T. b. brucei 427 and TREU 927 in
previously published reports [5,11]. However when brucpain
RNAi was induced by tetracycline, the number of parasites
migrating across the barrier was reduced by 50%
(1.10E+0366.35E+02), (p=0.003). The human BMEC transen-
dothelial electrical resistance (TEER) at the end of the experiment
was 30.461.2 ohms (p=0.00002), indicating that barrier integrity
was maintained for all T. b. brucei treatment conditions. To rule out
any effect of tetracycline on the in vitro BBB model other than
induces RNAi, trypanosomes (pZJMTbRho) were pretreated with
tetracycline, but the antibiotic was then removed and the parasites
incubated with human BMEC overnight. The number of parasites
crossing the BMEC was the same as control (with tetracycline),
demonstrating that tetracycline has no effect on endothelial cells
(data not shown). Experiments were repeated twice with the same
result. In summary, the data show that knockdown of brucipain
transcripts by RNAi led to reduced protease activity but no effect
on parasitemia or splenomegaly. However the prolonged survival
of some of the infected mice might be due to inability of the
parasite to efficiently enter the CNS.
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Figure 4. Parasite traversal across human BMEC. Transwell inserts containing human BMEC (initial TEER= 26.3 V) were incubated with 36105
pZJMTbRho RNAi trypanosomes (+/2tetracycline) and the number of parasites that crossed the BMEC monolayers into the bottom wells determined.
All values represent the mean6SEM of triplicate determinations.
doi:10.1371/journal.pntd.0000298.g004
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